Vertex to acquire Seattle biotech for $4.9B
Vertex Pharmaceuticals Inc. has agreed to buy a Seattle-based biotech developing a drug to treat kidney disease for $4.9 billion, the biggest acquisition in the Boston company ’s history.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
More News: Biotechnology | Health Management | Mergers and Aquisitions | Pharmaceuticals | Urology & Nephrology